S Meshinchi

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
    S Meshinchi
    The Fred Hutchinson Cancer Research Center, and University of Washington Medical Center, Seattle, WA 98103, USA
    Blood 97:89-94. 2001
  2. pmc Structural and functional alterations of FLT3 in acute myeloid leukemia
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:4263-9. 2009
  3. pmc Clinical implications of FLT3 mutations in pediatric AML
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
    Blood 108:3654-61. 2006
  4. pmc Structural and numerical variation of FLT3/ITD in pediatric AML
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, USA
    Blood 111:4930-3. 2008
  5. ncbi request reprint Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia
    Soheil Meshinchi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:706-13. 2003
  6. ncbi request reprint Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia
    S Meshinchi
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Pediatr Hematol Oncol 23:585-90. 2001
  7. ncbi request reprint Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4 100, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:1474-9. 2003
  8. pmc Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
    Phoenix A Ho
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:702-10. 2010
  9. ncbi request reprint Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
    William Tse
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Blood 104:3058-63. 2004
  10. ncbi request reprint FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
    D L Stirewalt
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 97:3589-95. 2001

Detail Information

Publications34

  1. ncbi request reprint Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
    S Meshinchi
    The Fred Hutchinson Cancer Research Center, and University of Washington Medical Center, Seattle, WA 98103, USA
    Blood 97:89-94. 2001
    ..002). Multivariate analysis demonstrated that presence of the Flt3/ITD was the single most significant, independent prognostic factor for poor outcome (P =.009) in pediatric AML...
  2. pmc Structural and functional alterations of FLT3 in acute myeloid leukemia
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 15:4263-9. 2009
    ..FLT3 inhibitors are under evaluation for their efficacy in AML patients with FLT3 mutations...
  3. pmc Clinical implications of FLT3 mutations in pediatric AML
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
    Blood 108:3654-61. 2006
    ..001) or with FLT3/WT (55%, P < .001). ITD-AR defines the prognostic significance in FLT3/ITD-positive AML, and ITD-AR greater than 0.4 is a significant and independent prognostic factor for relapse in pediatric AML...
  4. pmc Structural and numerical variation of FLT3/ITD in pediatric AML
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, USA
    Blood 111:4930-3. 2008
    ..035), while the presence of more than 1 ITD was not clinically significant. Physical characteristics including the length of FLT3/ITD may influence FLT3 activation state by altering its structure and may impact response to therapy...
  5. ncbi request reprint Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia
    Soheil Meshinchi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:706-13. 2003
    ..Because a higher tumor burden at the time of second HSCT was associated with a higher risk of subsequent relapse, patients might benefit from reinduction therapy before the second HSCT...
  6. ncbi request reprint Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia
    S Meshinchi
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Pediatr Hematol Oncol 23:585-90. 2001
    ..We compared multidimensional flow cytometry (MDF) with morphology in evaluating early marrow response to induction chemotherapy in pediatric ALL...
  7. ncbi request reprint Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4 100, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:1474-9. 2003
    ..38). Activating mutations in the RTK/ras signaling pathway are common in pediatric AML, and their presence may identify a population at higher risk of poor outcome who may benefit from allogeneic BM transplantation...
  8. pmc Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
    Phoenix A Ho
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:702-10. 2010
    ..The clinical trials are registered at www.clinicaltrials.gov as #NCT00002798 and #NCT00070174...
  9. ncbi request reprint Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
    William Tse
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Blood 104:3058-63. 2004
    ..01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis...
  10. ncbi request reprint FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
    D L Stirewalt
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 97:3589-95. 2001
    ..Blood. 2001;97:3589-3595)..
  11. ncbi request reprint Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
    Donna L Johnston
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 123:431-5. 2003
    ..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy...
  12. pmc Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
    Jessica A Pollard
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 115:2372-9. 2010
    ..Two of 4 studies included in this analysis are registered at http://clinicaltrials.gov as NCT00002798 (CCG-2961) and NCT00070174 (COG AAML03P1)...
  13. pmc Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
    Phoenix A Ho
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 113:6558-66. 2009
    ..24, P = .047). As CEBPA mutations are associated with lower relapse rate and improved survival, CEBPA mutation analysis needs to be incorporated into initial screening for risk identification and therapy allocation at diagnosis...
  14. ncbi request reprint Identification of genes with abnormal expression changes in acute myeloid leukemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Genes Chromosomes Cancer 47:8-20. 2008
    ..Future studies will determine their potential role in leukemogenesis and their clinical significance...
  15. pmc FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia
    Jessica A Pollard
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D2 373, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 108:2764-9. 2006
    ..002). This study suggests that FLT3/ITD involvement in CD34(+)/CD33(-) precursors is heterogeneous and that detection of the mutation in the less-mature progenitor population may be associated with disease resistance...
  16. doi request reprint Receptor tyrosine kinase alterations in AML - biology and therapy
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Treat Res 145:85-108. 2010
    ..The purpose of this chapter is to review the biology of receptor tyrosine kinases (RTKs) in AML, exploring how RTKs are being used as novel prognostic factors and potential therapeutic targets...
  17. pmc Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
    Derek L Stirewalt
    Fred Hutchinson Cancer Research Center, D5 380, 1100 Fairview Ave N Seattle, WA 98109, USA
    Blood 107:3724-6. 2006
    ..072) and RFS (estimated 5-year RFS: large = 13%, small = 27%, and no ITD = 34%, P = .017). These studies suggest that ITD size may have prognostic significance...
  18. ncbi request reprint Molecular targets in acute myelogenous leukemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, The Division of Oncology, University of Washington, Seattle 98109, USA
    Blood Rev 17:15-23. 2003
    ..After reviewing these two pathways, we explore some of the targeted therapies directed at these pathways that are under development for AML, many of which are already in clinical trials...
  19. ncbi request reprint Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Oncology, University of Washington, Seattle, WA 98109, USA
    Br J Haematol 124:481-4. 2004
    ..Novel missense point mutations were found in exon 14, suggesting additional investigations should be performed in AML and other haematopoietic malignancies, using this sensitive technique...
  20. pmc High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:2831-8. 2010
    ..To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML)...
  21. pmc WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group
    Phoenix A Ho
    Fred Hutchinson Cancer Research Center, D2 373, 1100 Fairview Ave N, Seattle, WA 98103, USA
    J Clin Oncol 29:704-11. 2011
    ..To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML)...
  22. pmc Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
    P A Ho
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leukemia 24:909-13. 2010
    ..Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML...
  23. ncbi request reprint Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, University of Washington, Department of Pediatrics, Division of Clinical Research, Seattle, Washington, USA
    Oncologist 12:341-55. 2007
    ..This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens...
  24. ncbi request reprint Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Center, Seattle, WA, USA
    Curr Oncol Rep 5:489-97. 2003
    ..This review describes prognostic factors that play a major role in the outcome of children with AML and their potential use for treatment stratification in pediatric AML trials...
  25. ncbi request reprint Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse
    Blythe Thomson
    Seattle Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    Pediatr Blood Cancer 43:571-9. 2004
    ..The ability to achieve a durable second remission is complicated by toxicity and resistant disease. We report a novel combination of chemotherapy for relapsed pediatric ALL...
  26. pmc Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
    D L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood Cancer J 4:e208. 2014
    ..Although the etiology underlying the development of CN-LOH remains to be clarified, the disruption in recombination/DNA repair pathway, which is present before the development of LOH, may have a role. ..
  27. pmc The incidence and clinical significance of nucleophosmin mutations in childhood AML
    Patrick Brown
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 110:979-85. 2007
    ..NPMc(+) does not abrogate the negative prognostic influence of FLT3/ITD mutations, but may contribute to risk stratification in children who lack FLT3/ITD mutations by identifying a group with superior prognosis...
  28. pmc Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Blood 108:74-80. 2006
    ..Fewer black children than expected had an available family marrow donor...
  29. ncbi request reprint Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
    Norman J Lacayo
    Division of Pediatric Hematology Oncology, Stanford University School of Medicine, Palo Alto, CA, USA
    Blood 104:2646-54. 2004
    ..0001). Thus, gene expression profiling identified AML patients with divergent prognoses within the FLT3-MU group, and the RUNX3 to ATRX expression ratio should be a useful prognostic indicator in these patients...
  30. ncbi request reprint Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
    Patrick Brown
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Blood 104:1841-9. 2004
    ..Clinical testing of FLT3 inhibitors as molecularly targeted agents for the improvement of outcome of pediatric AML patients is warranted...
  31. ncbi request reprint Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
    Mignon L Loh
    Department of Pediatrics, University of California, Rm HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 103:2325-31. 2004
    ..We conclude that SHP-2 is an important cellular PTPase that is mutated in myeloid malignancies. Further investigation is required to clarify how these mutant proteins interact with Ras and other effectors to deregulate myeloid growth...
  32. ncbi request reprint FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Blood 102:2387-94. 2003
    ..However, poor outcomes in FLT3/ITD-positive patients could not be attributed to increased in vitro cellular drug resistance...
  33. ncbi request reprint Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
    Soheil Meshinchi
    Blood 108:400; author reply 400-1. 2006
  34. pmc Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
    Draga Barbaric
    Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
    Blood 109:2314-21. 2007
    ..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...

Research Grants8

  1. Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2004
    ..This grant project will undertake an extensive evaluation of Flt3 mutations in the largest patient population tested to date and will correlate the data with other biologic markers. ..
  2. Biology/prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2005
    ..The data generated from this study will identify AML patients at high-risk of relapse early in the course of their disease, and will be used to guide therapy in risk-based approach in future trials. ..
  3. Accurate Prediction of Acute Myeloid Leukemia Relapse
    Soheil Meshinchi; Fiscal Year: 2005
    ..With these enhancements and modifications, we believe we will be able to accurately predict relapse in more than 80% of children with AML who achieve remission. ..
  4. Biology and Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2006
    ..The data generated from this study will identify AML patients at high-risk of relapse early in the course of their disease, and will be used to guide therapy in risk-based approach in future trials. ..
  5. Biology and Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2007
    ..The data generated from this study will identify AML patients at high-risk of relapse early in the course of their disease, and will be used to guide therapy in risk-based approach in future trials. ..
  6. Biology and Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2009
    ..The data generated from this study will identify AML patients at high-risk of relapse early in the course of their disease, and will be used to guide therapy in risk-based approach in future trials. ..
  7. Biology and Prognostic implications of Flt3 mutations in AML
    Soheil Meshinchi; Fiscal Year: 2009
    ..The data generated from this study will identify AML patients at high-risk of relapse early in the course of their disease, and will be used to guide therapy in risk-based approach in future trials. ..